Cargando…

FXYD3: A Promising Biomarker for Urothelial Carcinoma

OBJECTIVE: Urothelial carcinoma (UC) of the kidney is a relatively rare but aggressive form of kidney cancer. Differential diagnosis of renal UC from renal cell carcinoma (RCC) can be difficult, but is critical for correct patient management. We aimed to use global gene expression profiling to ident...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, ZhongFa, Pang, See-Tong, Kasper, Katherine A., Luan, Chunyan, Wondergem, Bill, Lin, Fan, Chuang, Cheng-Keng, Teh, Bin Tean, Yang, Ximing J.
Formato:	Texto
Lenguaje:	English
Publicado:	Libertas Academica 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076016/ https://www.ncbi.nlm.nih.gov/pubmed/21499437 http://dx.doi.org/10.4137/BMI.S6487

Ejemplares similares

Chronic Kidney Disease and Upper Tract Urothelial Carcinomas
por: Wang, Li-Jen, et al.
Publicado: (2014)

Upper Tract Urothelial Carcinomas in Patients with Chronic Kidney Disease: Relationship with Diagnostic Challenge
por: Wang, Li-Jen, et al.
Publicado: (2014)

Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder
por: Zhang, Zhongfa, et al.
Publicado: (2010)

FXYD6 is a new biomarker of cholangiocarcinoma
por: CHEN, XIONGFEI, et al.
Publicado: (2014)

Displacement of Native FXYD Protein From Na(+)/K(+)-ATPase With Novel FXYD Peptide Derivatives: Effects on Doxorubicin Cytotoxicity
por: Liu, Chia-Chi, et al.
Publicado: (2022)

What FXYDs fix
por: Habeck, Michael, et al.
Publicado: (2021)

A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression
por: Zhang, Zhongfa, et al.
Publicado: (2010)

Impaired AQP2 trafficking in Fxyd1 knockout mice: A role for FXYD1 in regulated vesicular transport
por: Arystarkhova, Elena, et al.
Publicado: (2017)

FXYD proteins and sodium pump regulatory mechanisms
por: Yap, John Q., et al.
Publicado: (2021)

FXYD6 promotes thermal nociception by regulating TRPV1
por: Luo, Hao, et al.
Publicado: (2021)

Expression and clinical significance of FXYD3 in endometrial cancer
por: LI, YIFEI, et al.
Publicado: (2014)

Expression and Significance of FXYD-3 Protein in Gastric Adenocarcinoma
por: Zhu, Zhen-Long, et al.
Publicado: (2010)

Low PTEN expression and overexpression of phosphorylated Akt(Ser473) and Akt(Thr308) are associated with poor overall survival in upper tract urothelial carcinoma
por: Weng, Wen-Hui, et al.
Publicado: (2020)

Prognostic significance of sodium-potassium ATPase regulator, FXYD3, in human hepatocellular carcinoma
por: Wang, Li-Juan, et al.
Publicado: (2018)

FXYD-3 expression in relation to local recurrence of rectal cancer
por: Loftas, Per, et al.
Publicado: (2016)

FXYD5: Na(+)/K(+)-ATPase Regulator in Health and Disease
por: Lubarski Gotliv, Irina
Publicado: (2016)

FXYD6 overexpression in HBV-related hepatocellular carcinoma with cirrhosis
por: Chen, Xiongfei, et al.
Publicado: (2020)

Risk Stratification of Upper Urinary Tract Urothelial Carcinoma Patients for Survival Prediction: A Simple Summation Scoring Method
por: Wang, Li-Jen, et al.
Publicado: (2018)

Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma
por: Hsu, I-Ling, et al.
Publicado: (2016)

FXYD6: a novel therapeutic target toward hepatocellular carcinoma
por: Gao, Qian, et al.
Publicado: (2014)

FXYD5 Is an Essential Mediator of the Inflammatory Response during Lung Injury
por: Brazee, Patricia L., et al.
Publicado: (2017)

Expression mode and prognostic value of FXYD family members in colon cancer
por: Jin, Ming, et al.
Publicado: (2021)

Epigenetic remodelling of Fxyd1 promoters in developing heart and brain tissues
por: Cuomo, Mariella, et al.
Publicado: (2022)

Predictors of Intravesical Recurrence After Radical Nephroureterectomy and Prognosis in Patients with Upper Tract Urothelial Carcinoma
por: Li, Yun-Ren, et al.
Publicado: (2020)

Label-Free Biochips for Accurate Detection of Prostate Cancer in the Clinic: Dual Biomarkers and Circulating Tumor Cells
por: Pan, Lung-Hsuan, et al.
Publicado: (2017)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Overexpression of FXYD-3 Is Involved in the Tumorigenesis and Development of Esophageal Squamous Cell Carcinoma
por: Zhu, Zhen-Long, et al.
Publicado: (2013)

Renal Mg handling, FXYD2 and the central role of the Na,K‐ATPase
por: Mayan, Haim, et al.
Publicado: (2018)

FXYD protein isoforms differentially modulate human Na/K pump function
por: Meyer, Dylan J., et al.
Publicado: (2020)

Effect of differentiation, de novo innervation, and electrical pulse stimulation on mRNA and protein expression of Na(+),K(+)-ATPase, FXYD1, and FXYD5 in cultured human skeletal muscle cells
por: Jan, Vid, et al.
Publicado: (2021)

LncRNA LINC01503 aggravates the progression of cervical cancer through sponging miR-342-3p to mediate FXYD3 expression
por: Peng, Xing, et al.
Publicado: (2020)

Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma
por: Zeng, Shuxiong, et al.
Publicado: (2017)

Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
por: Vallois, David, et al.
Publicado: (2014)

FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas
por: Raman, Pichai, et al.
Publicado: (2015)

Fxyd2 regulates Aδ- and C-fiber mechanosensitivity and is required for the maintenance of neuropathic pain
por: Ventéo, Stéphanie, et al.
Publicado: (2016)

FXYD3 Expression Predicts Poor Prognosis in Renal Cell Carcinoma with Immunosuppressive Tumor Microenvironment
por: Yonekura, Satoru, et al.
Publicado: (2022)

FXYD domain containing ion transport regulator 5 (FXYD5) silencing promotes cell viability and alleviates inflammatory response in cerulein-induced AR42J cells by blocking JAK2/STAT3 signaling pathway
por: Ding, Licheng, et al.
Publicado: (2022)

FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways
por: Besso, María José, et al.
Publicado: (2019)

Serum Cystatin C Level Is Not a Promising Biomarker for Predicting Clinicopathological Characteristics of Bladder Urothelial Tumors
por: Wang, Hui, et al.
Publicado: (2018)

Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancer
por: Valdés, Alberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hgniq8fqk8f96qb38so7qgltjv